Septerna (NASDAQ:SEPN) Insider Samira Shaikhly Sells 5,935 Shares of Stock

Posted by Brian Himes on Jun 4th, 2026

Septerna, Inc. (NASDAQ:SEPN – Get Free Report) insider Samira Shaikhly sold 5,935 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $28.93, for a total transaction of $171,699.55. Following the sale, the insider directly owned 793 shares of the company’s stock, valued at approximately $22,941.49. This represents a 88.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Samira Shaikhly also recently made the following trade(s):

On Tuesday, May 26th, Samira Shaikhly sold 11,798 shares of Septerna stock. The stock was sold at an average price of $30.06, for a total transaction of $354,647.88.

Septerna Stock Performance

NASDAQ SEPN opened at $30.55 on Thursday. Septerna, Inc. has a twelve month low of $9.70 and a twelve month high of $32.63. The stock has a market capitalization of $1.38 billion, a PE ratio of -37.72 and a beta of 2.39. The stock has a 50-day simple moving average of $25.85 and a 200 day simple moving average of $26.38.

Septerna (NASDAQ:SEPN – Get Free Report) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.23. Septerna had a negative return on equity of 12.72% and a negative net margin of 49.88%.The company had revenue of $26.52 million during the quarter, compared to analysts’ expectations of $16.98 million. As a group, equities research analysts forecast that Septerna, Inc. will post -1.57 EPS for the current fiscal year.

Institutional Investors Weigh In On Septerna

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC bought a new position in shares of Septerna in the first quarter worth about $21,334,000. First Light Asset Management LLC grew its stake in shares of Septerna by 18.0% during the first quarter. First Light Asset Management LLC now owns 732,860 shares of the company’s stock valued at $17,611,000 after purchasing an additional 112,049 shares during the last quarter. Renaissance Technologies LLC bought a new stake in shares of Septerna during the first quarter valued at approximately $906,000. Swiss National Bank acquired a new stake in shares of Septerna in the first quarter valued at approximately $531,000. Finally, Bank of New York Mellon Corp increased its holdings in shares of Septerna by 6.1% in the first quarter. Bank of New York Mellon Corp now owns 58,709 shares of the company’s stock valued at $1,411,000 after purchasing an additional 3,377 shares in the last quarter.

Analyst Ratings Changes

Several analysts have weighed in on SEPN shares. Wall Street Zen cut shares of Septerna from a “buy” rating to a “hold” rating in a research note on Saturday, March 14th. HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Septerna in a report on Wednesday, May 13th. JPMorgan Chase & Co. increased their price target on Septerna from $34.00 to $38.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Septerna in a report on Tuesday, April 21st. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $60.00 price objective on shares of Septerna in a research report on Tuesday, March 10th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $43.13.

View Our Latest Stock Analysis on Septerna

About Septerna

(Get Free Report)

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.